Ashland Inc. reported third quarter fiscal 2026 sales of $497 million, up seven percent from the prior-year quarter, and reaffirmed its full-year sales and Adjusted EBITDA guidance. Income from continuing operations was $41 million, or $0.89 per diluted share, while Adjusted EBITDA declined four percent to $109 million. Sales volumes rose six percent across all business units, with Life Sciences and Personal Care driving growth, though lower Specialty Additives and Intermediates earnings weighed on profitability. The company reaffirmed its fiscal 2026 sales outlook of $1,835 to $1,870 million and Adjusted EBITDA of $385 to $400 million, while revising adjusted EPS growth expectations to low-to-mid single digits due to a higher tax rate.
Ashland Global Holdings IncSales up 7%, reaffirmed full-year guidance, though adjusted EBITDA declined and EPS growth revised down.